Fluorine-18 Radiolabeled PET Tracers for Imaging Monoamine Transporters: Dopamine, Serotonin, and Norepinephrine

PET Clinics

Volumn 4, Issue 1, 2009, Pages 101-128

  Stehouwer, Jeffrey S ^a,b   Goodman, Mark M ^a,b  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Wesley Woods Geriatric Hospital   (United States)

Author keywords

Dopamine transporter; Fluorine 18 PET; Norepinephrine transporter; Serotonin transporter; Tropanes

Indexed keywords

1 [2 [(4 FLUOROPHENYL)(PHENYL)METHOXY]ETHYL] 4 (3 PHENYLPROPYL)PIPERAZINE; 1,2,3,5,6,10B HEXAHYDRO 6 (4 METHYLTHIOPHENYL)PYRROLO[2,1 A]ISOQUINOLINE; 3BETA (4 FLUOROPHENYL) 2BETA TROPANECARBOXYLIC ACID METHYL ESTER; 6 NITROQUIPAZINE; CARBON 11; CITALOPRAM; COCAINE; DOPAMINE TRANSPORTER; FLUORINE 18; FLUOXETINE; NISOXETINE; NORADRENALIN TRANSPORTER; REBOXETINE; SEROTONIN TRANSPORTER; TRACER; TROPANE DERIVATIVE; TROPARIL; VANOXERINE;

BINDING AFFINITY; BRAIN REGION; DEFLUORINATION; DRUG HALF LIFE; HUMAN; IMAGE ANALYSIS; ISOTOPE LABELING; LIPOPHILICITY; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RECEPTOR BINDING; RECEPTOR OCCUPANCY; REVIEW; RHESUS MONKEY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

EID: 68449097096     PISSN: 15568598     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cpet.2009.05.006     Document Type: Review

References (297)

1. Rudnick G., and Clark J. From synapse to vesicle: the reuptake and storage of biogenic amine neurotransmitters. Biochim Biophys Acta 1144 (1993) 249-263
2. Nelson N. The family of Na+/Cl- neurotransmitter transporters. J Neurochem 71 (1998) 1785-1803
3. Eisenhofer G. The role of neuronal and extraneuronal plasma membrane transporters in the inactivation of peripheral catecholamines. Pharmacol Ther 91 (2001) 35-62
4. Miller G.M., Yatin S.M., De La Garza R., et al. Cloning of dopamine, norepinephrine and serotonin transporters from monkey brain: relevance to cocaine sensitivity. Brain Res Mol Brain Res 87 (2001) 124-143
5. Gainetdinov R.R., and Caron M.G. Monoamine transporters: from genes to behavior. Annu Rev Pharmacol Toxicol 43 (2003) 261-284
6. Torres G.E., Gainetdinov R.R., and Caron M.G. Plasma membrane monoamine transporters: structure, regulation and function. Nat Rev Neurosci 4 (2003) 13-25
7. Lester H.A., Cao Y., and Mager S. Listening to neurotransmitter transporters. Neuron 17 (1996) 807-810
8. Melikian H.E. Neurotransmitter transporter trafficking: endocytosis, recycling, and regulation. Pharmacol Ther 104 (2004) 17-27
9. Iversen L. Neurotransmitter transporters: fruitful targets for CNS drug discovery. Mol Psychiatry 5 (2000) 357-362
10. Carroll F.I., Howell L.L., and Kuhar M.J. Pharmacotherapies for treatment of cocaine abuse: preclinical aspects. J Med Chem 42 (1999) 2721-2736
11. Carroll F.I. 2002 Medicinal Chemistry Division award address: monoamine transporters and opioid receptors. Targets for addiction therapy. J Med Chem 46 (2003) 1775-1794
12. Volkow N.D., Fowler J.S., Gatley S.J., et al. PET evaluation of the dopamine system of the human brain. J Nucl Med 37 (1996) 1242-1256
13. Laakso A., and Hietala J. PET studies of brain monoamine transporters. Curr Pharm Des 6 (2000) 1611-1623
14. Jaffer F.A., and Weissleder R. Molecular imaging in the clinical arena. J Am Med Assoc 293 (2005) 855-862
15. Hammoud D.A., Hoffman J.M., and Pomper M.G. Molecular neuroimaging: from conventional to emerging techniques. Radiology 245 (2007) 21-42
16. Meyer J.H. Imaging the serotonin transporter during major depressive disorder and antidepressant treatment. J Psychiatry Neurosci 32 (2007) 86-102
17. Brooks D.J. Neuroimaging in Parkinson's disease. NeuroRx 1 (2004) 243-254
18. Aboagye E.O., Price P.M., and Jones T. In vivo pharmacokinetics and pharmacodynamics in drug development using positron-emission tomography. Drug Discov Today 6 (2001) 293-302
19. Laruelle M., Slifstein M., and Huang Y. Positron emission tomography: imaging and quantification of neurotransporter availability. Methods 27 (2002) 287-299
20. Talbot P.S., and Laruelle M. The role of in vivo molecular imaging with PET and SPECT in the elucidation of psychiatric drug action and new drug development. Eur Neuropsychopharmacol 12 (2002) 503-511
21. Guilloteau D., and Chalon S. PET and SPECT exploration of central monoaminergic transporters for the development of new drugs and treatments in brain disorders. Curr Pharm Des 11 (2005) 3237-3245
22. Lee C.M., and Farde L. Using positron emission tomography to facilitate CNS drug development. Trends Pharmacol Sci 27 (2006) 310-316
23. Hargreaves R.J. The role of molecular imaging in drug discovery and development. Clin Pharmacol Ther 83 (2008) 349-353
24. Takano A., Suzuki K., Kosaka J., et al. A dose-finding study of duloxetine based on serotonin transporter occupancy. Psychopharmacology 185 (2006) 395-399
25. Schlyer D.J. PET tracers and radiochemistry. Ann Acad Med Singap 33 (2004) 146-154
26. Ametamey S.M., Honer M., and Schubiger P.A. Molecular imaging with PET. Chem Rev 108 (2008) 1501-1516
27. 13N radiolabels for positron emission tomography. Angew Chem Int Ed Engl 47 (2008) 8998-9033
28. In: Wernick M.N., Aarsvold J., (Eds). Emission tomography: the fundamentals of PET and SPECT (2004), Elsevier Academic Press, San Diego (CA); London, UK 179
29. Levin C.S., and Hoffman E.J. Calculation of positron range and its effect on the fundamental limit of positron emission tomography system spatial resolution. Phys Med Biol 44 (1999) 781-799
30. Smart B.E. Fluorine substituent effects (on bioactivity). J Fluor Chem 109 (2001) 3-11
31. Böhm H.J., Banner D., Bendels S., et al. Fluorine in medicinal chemistry. Chembiochem 5 (2004) 637-643
32. DiMagno S.G., and Sun H. The strength of weak interactions: aromatic fluorine in drug design. Curr Top Med Chem 6 (2006) 1473-1482
33. a and log D values. ChemMedChem 1 (2006) 611-621
34. Sun S., and Adejare A. Fluorinated molecules as drugs and imaging agents in the CNS. Curr Top Med Chem 6 (2006) 1457-1464
35. Müller K., Faeh C., and Diederich F. Fluorine in pharmaceuticals: looking beyond intuition. Science 317 (2007) 1881-1886
36. Hagmann W.K. The many roles for fluorine in medicinal chemistry. J Med Chem 51 (2008) 4359-4369
37. Prakash G.K.S., and Hu J. Selective fluoroalkylations with fluorinated sulfones, sulfoxides, and sulfides. Acc Chem Res 40 (2007) 921-930
38. Kirk K.L. Fluorination in medicinal chemistry: methods, strategies, and recent developments. Org Process Res Dev 12 (2008) 305-321
39. Lasne M.C., Perrio C., Rouden J., et al. Chemistry of β+-emitting compounds based on fluorine-18. Top Curr Chem 222 (2002) 201-258
40. 18F]fluoride ion. Eur J Org Chem (2008) 2853-2873
41. 18F]fluoride ion: nucleophilic fluorination as the detagging process. Angew Chem Int Ed Engl 48 (2009) 586-589
42. Logan J., Fowler J.S., Volkow N.D., et al. Distribution volume ratios without blood sampling from graphical analysis of PET data. J Cereb Blood Flow Metab 16 (1996) 834-840
43. Morris E.D., Alpert N.M., and Fischman A.J. Comparison of two compartmental models for describing receptor ligand kinetics and receptor availability in multiple injection PET studies. J Cereb Blood Flow Metab 16 (1996) 841-853
44. Laruelle M. The role of model-based methods in the development of single scan techniques. Nucl Med Biol 27 (2000) 637-642
45. Logan J. Graphical analysis of PET data applied to reversible and irreversible tracers. Nucl Med Biol 27 (2000) 661-670
46. Lammertsma A.A. Radioligand studies: imaging and quantitative analysis. Eur Neuropsychopharmacol 12 (2002) 513-516
47. Bentourkia M., and Zaidi H. Tracer kinetic modeling in PET. PET Clinics 2 (2007) 267-277
48. Dischino D.D., Welch M.J., Kilbourn M.R., et al. Relationship between lipophilicity and brain extraction of C-11-labeled radiopharmaceuticals. J Nucl Med 24 (1983) 1030-1038
49. Elfving B., Bjørnholm B., Ebert B., et al. Binding characteristics of selective serotonin reuptake inhibitors with relation to emission tomography studies. Synapse 41 (2001) 203-211
50. Waterhouse R.N. Determination of lipophilicity and its use as a predictor of blood-brain barrier penetration of molecular imaging agents. Mol Imaging Biol 5 (2003) 376-389
51. Kilty J.E., Lorang D., and Amara S.G. Cloning and expression of a cocaine-sensitive rat dopamine transporter. Science 254 (1991) 578-579
52. Shimada S., Kitayama S., Lin C.L., et al. Cloning and expression of a cocaine-sensitive dopamine transporter complementary DNA. Science 254 (1991) 576-578
53. Giros B., El Mestikawy S., Godinot N., et al. Cloning, pharmacological characterization, and chromosome assignment of the human dopamine transporter. Mol Pharmacol 42 (1992) 383-390
54. Ciliax B.J., Heilman C., Demchyshyn L.L., et al. The dopamine transporter: immunochemical characterization and localization in brain. J Neurosci 15 (1995) 1714-1723
55. Nirenberg M.J., Vaughan R.A., Uhl G.R., et al. The dopamine transporter is localized to dendritic and axonal plasma membranes of nigrostriatal dopaminergic neurons. J Neurosci 16 (1996) 436-447
56. Ciliax B.J., Drash G.W., Staley J.K., et al. Immunocytochemical localization of the dopamine transporter in human brain. J Comp Neurol 409 (1999) 38-56
57. Kaufman M.J., Spealman R.D., and Madras B.K. Distribution of cocaine recognition sites in monkey brain: I. In vitro autoradiography with [3H]CFT. Synapse 9 (1991) 177-187
58. Niznik H.B., Fogel E.F., Fassos F.F., et al. The dopamine transporter is absent in parkinsonian putamen and reduced in the caudate nucleus. J Neurochem 56 (1991) 192-198
59. Chinaglia G., Alvarez F.J., Probst A., et al. Mesostriatal and mesolimbic dopamine uptake binding sites are reduced in Parkinson's disease and progressive supranuclear palsy: a quantitative autoradiographic study using [3H]Mazindol. Neuroscience 49 (1992) 317-327
60. Dawson T.M., and Dawson V.L. Molecular pathways of neurodegeneration in Parkinson's disease. Science 302 (2003) 819-822
61. Mazei-Robison M.S., Couch R.S., Shelton R.C., et al. Sequence variation in the human dopamine transporter gene in children with attention deficit hyperactivity disorder. Neuropharmacology 49 (2005) 724-736
62. Singer H.S., Hahn I.H., and Moran T.H. Abnormal dopamine uptake sites in postmortem striatum from patients with Tourette's syndrome. Ann Neurol 30 (1991) 558-562
63. Marek K., Jennings D., Tamagnan G., et al. Biomarkers for Parkinson's disease: tools to assess Parkinson's disease onset and progression. Ann Neurol 64 Suppl (2008) S111-S121
64. Heikkila R.E., and Manzino L. Behavioral properties of GBR 12909, GBR 13069 and GBR 13098: specific inhibitors of dopamine uptake. Eur J Pharmacol 103 (1984) 241-248
65. Andersen P.H. The dopamine uptake inhibitor GBR 12909: selectivity and molecular mechanism of action. Eur J Pharmacol 166 (1989) 493-504
66. 18F]GBR 13119, a dopamine uptake inhibitor, in CD-1 and C57BL/6 mice. Eur J Pharmacol 166 (1989) 331-334
67. 18F]GBR 13119 binding autoradiography in rat brain. J Neurochem 55 (1990) 619-623
68. 18F]GBR 12909 for human studies of dopamine reuptake sites. [abstract]. J Nucl Med 31 836 (1990) 901
69. Koeppe R.A., Kilbourn M.R., Frey K.A., et al. Imaging and kinetic modeling of [F-18]GBR 12909, a dopamine uptake inhibitor. [abstract]. J Nucl Med 31 55 (1990) 720
70. 18F-labeled ligands. [abstract]. J Nucl Med 31 823 (1990) 898
71. 18F]GBR 13119 binding to the dopamine uptake site. Eur J Pharmacol 216 (1992) 109-112
72. 18F]GBR 13119: imaging the dopamine uptake system in vivo. Nucl Med Biol (Int J Radiat Appl Instrum Part B) 16 (1989) 569-576
73. 18F]NNC 12-0818: two potential radioligands for the dopamine transporter. Appl Radiat Isot 46 (1995) 323-328
74. Wolf W.A., and Kuhn D.M. Cocaine and serotonin neurochemistry. Neurochem Int 18 (1991) 33-38
75. Uhl G.R., Hall F.S., and Sora I. Cocaine, reward, movement and monoamine transporters. Mol Psychiatry 7 (2002) 21-26
76. Ritz M.C., Lamb R.J., Goldberg S.R., et al. Cocaine receptors on dopamine transporters are related to self-administration of cocaine. Science 237 (1987) 1219-1223
77. 3H-WIN 35,065-2, and 3H-WIN 35,428. Synapse 4 (1989) 390-392
78. 3H]dopamine uptake is similar in both the rat striatum and nucleus accumbens. Eur J Pharmacol 173 (1989) 215-217
79. Fowler J.S., Volkow N.D., Wolf A.P., et al. Mapping cocaine binding sites in human and baboon brain in vivo. Synapse 4 (1989) 371-377
80. Fowler J.S., Volkow N.D., MacGregor R.R., et al. Comparative PET studies of the kinetics and distribution of cocaine and cocaethylene in baboon brain. Synapse 12 (1992) 220-227
81. Yu D.W., Gatley S.J., Wolf A.P., et al. Synthesis of carbon-11 labeled iodinated cocaine derivatives and their distribution in baboon brain measured using positron emission tomography. J Med Chem 35 (1992) 2178-2183
82. 11C]cocaine metabolites contribute to PET images of the baboon brain. J Neurochem 62 (1994) 1154-1162
83. Kimmel H.L., Negus S.S., Wilcox K.M., et al. Relationship between rate of drug uptake in brain and behavioral pharmacology of monoamine transporter inhibitors in rhesus monkeys. Pharmacol Biochem Behav 90 (2008) 453-462
84. Kloss M.W., Rosen G.M., and Rauckman E.J. N-demethylation of cocaine to norcocaine. Mol Pharmacol 23 (1983) 482-485
85. Jindal S.P., and Lutz T. Mass spectrometric studies of cocaine disposition in animals and humans using stable isotope-labeled analogues. J Pharm Sci 78 (1989) 1009-1014
86. 123I]β-CIT determined with a gradient HPLC method. Nucl Med Biol 22 (1995) 971-976
87. Potter P.M., and Wadkins R.M. Carboxylesterases: detoxifying enzymes and targets for drug therapy. Curr Med Chem 13 (2006) 1045-1054
88. 11C]β-CIT labelled in two different positions. Nucl Med Biol 26 (1999) 343-350
89. Larsen N.A., Turner J.M., Stevens J., et al. Crystal structure of a bacterial cocaine esterase. Nat Struct Biol 9 (2002) 17-21
90. Clarke R.L., Daum S.J., Gambino A.J., et al. Compounds affecting the central nervous system. 4. 3β-Phenyltropane-2-carboxylic esters and analogs. J Med Chem 16 (1973) 1260-1267
91. Boja J.W., Carroll F.I., Rahman M.A., et al. New, potent cocaine analogs: ligand binding and transport studies in rat striatum. Eur J Pharmacol 184 (1990) 329-332
92. Carroll F.I., Gao Y., Rahman M.A., et al. Synthesis, ligand binding, QSAR, and CoMFA study of 3β-(p-substituted phenyl)tropane-2β-carboxylic acid methyl esters. J Med Chem 34 (1991) 2719-2725
93. Carroll F.I., Lewin A.H., Boja J.W., et al. Cocaine receptor: biochemical characterization and structure-activity relationships of cocaine analogues at the dopamine transporter. J Med Chem 35 (1992) 969-981
94. Kuhar M.J., McGirr K.M., Hunter R.G., et al. Studies of selected phenyltropanes at monoamine transporters. Drug Alcohol Depend 56 (1999) 9-15
95. Cook C.D., Carroll F.I., and Beardsley P.M. Cocaine-like discriminative stimulus effects of novel cocaine and 3-phenyltropane analogs in the rat. Psychopharmacology 159 (2001) 58-63
96. Singh S. Chemistry, design, and structure-activity relationship of cocaine antagonists. Chem Rev 100 (2000) 925-1024
97. Jin C., Navarro H.A., Page K., et al. Synthesis and monoamine transporter binding properties of 2β-[3'-(substituted benzyl)isoxazol-5-yl]- and 2β-[3'-methyl-4'-(substituted phenyl)isoxazol-5-yl]-3β-(substituted phenyl)tropanes. Bioorg Med Chem 16 (2008) 6682-6688
98. Jin C., Navarro H.A., and Carroll F.I. Development of 3-phenyltropane analogues with high affinity for the dopamine and serotonin transporters and low affinity for the norepinephrine transporter. J Med Chem 51 (2008) 8048-8056
99. 125I]RTI-55: a potent ligand for dopamine transporters. Eur J Pharmacol 194 (1991) 133-134
100. Meltzer P.C., Liang A.Y., Brownell A.L., et al. Substituted 3-phenyltropane analogs of cocaine: synthesis, inhibition of binding at cocaine recognition sites, and positron emission tomography imaging. J Med Chem 36 (1993) 855-862
101. 11C]WIN 35,428. Synapse 15 (1993) 130-142
102. 18F]-labelled cocaine analogues as potential dopamine transporter ligands for positron emission tomography. Nucl Med Biol 23 (1996) 141-146
103. 11C]β-CIT binding to monoamine transporters in the monkey and human brain. Synapse 16 (1994) 93-103
104. 11C]β-CFT. Nucl Med Biol 22 (1995) 965-970
105. 18F]fluoroethyl)nortropane) as a dopamine transporter ligand: a PET study in the conscious monkey brain. Synapse 54 (2004) 37-45
106. 18F]WIN 35,428), a radioligand to study the dopamine transporter with PET: biodistribution in rats. Synapse 23 (1996) 321-327
107. 18F]WIN 35,428), a radioligand to study the dopamine transporter with PET: characterization in human subjects. Synapse 28 (1998) 244-250
108. 18F]CFT are both sensitive PET markers to detect presynaptic dopaminergic hypofunction in early Parkinson's disease. Synapse 40 (2001) 193-200
109. 11C]β-CFT-FP, selective radioligands for visualisation of the dopamine transporter using positron emission tomography (PET). J Labelled Comp Radiopharm 43 (2000) 1235-1244
110. 18F]fluoropropyl)-2β-carbomethoxy-3β-(4-fluorophen yl)nortropane in rats. Nucl Med Biol 35 (2008) 177-183
111. Owens M.J., Morgan W.N., Plott S.J., et al. Neurotransmitter receptor and transporter binding profile of antidepressants and their metabolites. J Pharmacol Exp Ther 283 (1997) 1305-1322
112. Hiemke C., and Härtter S. Pharmacokinetics of selective serotonin reuptake inhibitors. Pharmacol Ther 85 (2000) 11-28
113. Neumeyer J.L., Tamagnan G., Wang S., et al. N-substituted analogs of 2β-carbomethoxy-3β-(4'-iodophenyl)tropane (β-CIT) with selective affinity to dopamine or serotonin transporters in rat forebrain. J Med Chem 39 (1996) 543-548
114. Neumeyer J.L., Wang S., Gao Y., et al. N-ω-Fluoroalkyl analogs of (1 R)-2β-carbomethoxy-3β-(4-iodophenyl)-tropane (β-CIT): radiotracers for positron emission tomography and single photon emission computed tomography imaging of dopamine transporters. J Med Chem 37 (1994) 1558-1561
115. Carroll F.I., Abraham P., Lewin A.H., et al. Isopropyl and phenyl esters of 3β-(4-substituted phenyl)tropan-2β-carboxylic acids: potent and selective compounds for the dopamine transporter. J Med Chem 35 (1992) 2497-2500
116. 123I] N-ω-fluoroalkyl-2β-carboxy-3β-(4-iodophenyl)nortropane esters in baboons. Nucl Med Biol 22 (1995) 211-219
117. Kuikka J.T., Bergström K.A., Ahonen A., et al. Comparison of iodine-123 labelled 2β-carbomethoxy-3β-(4-iodophenyl)tropane and 2β-carbomethoxy-3β-(4-iodophenyl)- N-(3-fluoropropyl)nortropane for imaging of the dopamine transporter in the living human brain. Eur J Nucl Med 22 (1995) 356-360
118. 11C]β-CIT-FE, a radioligand for quantitation of the dopamine transporter in the living brain using positron emission tomography. Synapse 22 (1996) 386-390
119. 11C]β-CIT-FP for quantitation of the dopamine transporter. Nucl Med Biol 24 (1997) 621-627
120. 18F] N-3-fluoropropyl-2-β-carbomethoxy-3-β-(4-iodophenyl) nortropane and the first human study with positron emission tomography. Nucl Med Biol 23 (1996) 999-1004
121. Kazumata K., Dhawan V., Chaly T., et al. Dopamine transporter imaging with fluorine-18-FPCIT and PET. J Nucl Med 39 (1998) 1521-1530
122. 18F]FPCIT binding in early stage Parkinson's disease: a PET study. Synapse 45 (2002) 125-133
123. 18F-FPCIT in human subjects. J Nucl Med 44 (2003) 961-966
124. 18F]FP-β-CIT and positron emission tomography. J Cereb Blood Flow Metab 27 (2007) 1397-1406
125. 18F]FP-CIT using a protic solvent system. Nucl Med Biol 34 (2007) 345-351
126. Goodman M.M., Keil R., Shoup T.M., et al. Fluorine-18-FPCT: a PET radiotracer for imaging dopamine transporters. J Nucl Med 38 (1997) 119-126
127. 18F-labeled FECNT: a selective radioligand for PET imaging of brain dopamine transporters. Nucl Med Biol 27 (2000) 1-12
128. Votaw J.R., Howell L.L., Martarello L., et al. Measurement of dopamine transporter occupancy for multiple injections of cocaine using a single injection of [F-18]FECNT. Synapse 44 (2002) 203-210
129. 18F]FECNT. J Nucl Med 42 (2001) 376-381
130. 18F-FECNT in non-human primates. Nucl Med Commun 25 (2004) 737-742
131. 18F]FECNT for human PET imaging studies. Appl Radiat Isot 63 (2005) 353-361
132. 18F-FECNT from mesylate precursor. Appl Radiat Isot 66 (2008) 1881-1885
133. 18F-FECNT. J Nucl Med 44 (2003) 855-861
134. 18F-FECNT: a polar radiometabolite confounds brain radioligand measurements. J Nucl Med 47 (2006) 520-527
135. Cumming P., Yokoi F., Chen A., et al. Pharmacokinetics of radiotracers in human plasma during positron emission tomography. Synapse 34 (1999) 124-134
136. Gillings N.M., Bender D., Falborg L., et al. Kinetics of the metabolism of four PET radioligands in living minipigs. Nucl Med Biol 28 (2001) 97-104
137. 11C]PK11195] and its metabolites in humans. Nucl Med Biol 32 (2005) 307-312
138. 11C]verapamil as PET tracer of P-glycoprotein function in the blood-brain barrier: kinetics and metabolism in the rat. Nucl Med Biol 32 (2005) 87-93
139. 11C]PE2I. Eur J Nucl Med Mol Imaging 34 (2007) 667-678
140. 18F]FDDNP and cerebral uptake of its labelled metabolites. Nucl Med Biol 35 (2008) 869-874
141. 18F] N-3-fluoropropyl-2-β-carbomethoxy-3-β(4' methylphenyl) nortropane (FPCMT). Appl Radiat Isot 51 (1999) 299-305
142. 18F]FECT. Nucl Med Biol 35 (2008) 75-82
143. Gu X.H., Zong R., Kula N.S., et al. Synthesis and biological evaluation of a series of novel N- or O-fluoroalkyl derivatives of tropane: potential positron emission tomography (PET) imaging agents for the dopamine transporter. Bioorg Med Chem Lett 11 (2001) 3049-3053
144. Peng X., Zhang A., Kula N.S., et al. Synthesis and amine transporter affinities of novel phenyltropane derivatives as potential positron emission tomography (PET) imaging agents. Bioorg Med Chem Lett 14 (2004) 5635-5639
145. 18F]MCL-322) as a PET radiotracer for imaging the dopamine transporter (DAT). Bioorg Med Chem 15 (2007) 4511-4519
146. 18F]FE@CIT, a new potential tracer for the dopamine transporter. Synapse 55 (2005) 73-79
147. 123I]FP-CIT. Nucl Med Biol 35 (2008) 475-479
148. Xing D., Chen P., Keil R., et al. Synthesis, biodistribution, and primate imaging of fluorine-18 labeled 2β-Carbo-1'-fluoro-2-propoxy-3β-(4-chlorophenyl)tropanes: ligands for the imaging of dopamine transporters by positron emission tomography. J Med Chem 43 (2000) 639-648
149. Mach R.H., Nader M.A., Ehrenkaufer R.L., et al. Fluorine-18-labeled tropane analogs for PET imaging studies of the dopamine transporter. Synapse 37 (2000) 109-117
150. 18F]fluorobut-2-en-1-yl)-2β-carbomethoxy-3β-(4-sub stituted-phenyl)nortropanes for imaging DAT by PET. J Labelled Comp Radiopharm 42 Suppl 1 (1999) S400
151. Goodman MM, Chen P. Fluoroalkenyl Nortropanes. 2000:World Patent Application WO2000064490. Published November 2, 2000.
152. Chalon S., Hall H., Saba W., et al. Pharmacological characterization of (E)- N-(4-Fluorobut-2-enyl)-2β-carbomethoxy-3β-(4'-tolyl)nortropane (LBT-999) as a highly promising fluorinated ligand for the dopamine transporter. J Pharmacol Exp Ther 317 (2006) 147-152
153. 11C]LBT-999, a selective radioligand for the visualisation of the dopamine transporter with PET. Bioorg Med Chem 14 (2006) 1115-1125
154. 18F]LBT-999, a selective radioligand for the visualization of the dopamine transporter with PET. J Labelled Comp Radiopharm 49 (2006) 687-698
155. 18F]LBT-999: a selective radioligand for the visualization of the dopamine transporter with PET. J Labelled Comp Radiopharm 50 (2007) 716-723
156. 11C]LBT-999: a suitable radioligand for investigation of extra-striatal dopamine transporter with PET. Synapse 61 (2007) 17-23
157. 18F]FBFNT. J Labelled Comp Radiopharm 50 Suppl 1 (2007) S335
158. Carroll F.I., Kotian P., Dehghani A., et al. Cocaine and 3β-(4'-substituted phenyl)tropane-2β-carboxylic acid ester and amide analogues: new high-affinity and selective compounds for the dopamine transporter. J Med Chem 38 (1995) 379-388
159. Dworkin S.I., Lambert P., Sizemore G.M., et al. RTI-113 administration reduces cocaine self-administration at high occupancy of dopamine transporter. Synapse 30 (1998) 49-55
160. Cook C.D., Carroll F.I., and Beardsley P.M. RTI 113, a 3-phenyltropane analog, produces long-lasting cocaine-like discriminative stimulus effects in rats and squirrel monkeys. Eur J Pharmacol 442 (2002) 93-98
161. Wilcox K.M., Lindsey K.P., Votaw J.R., et al. Self-administration of cocaine and the cocaine analog RTI-113: relationship to dopamine transporter occupancy determined by PET neuroimaging in rhesus monkeys. Synapse 43 (2002) 78-85
162. Tsukada H., Nishiyama S., Kakiuchi T., et al. Isoflurane anesthesia enhances the inhibitory effects of cocaine and GBR12909 on dopamine transporter: PET studies in combination with microdialysis in the monkey brain. Brain Res 849 (1999) 85-96
163. Miyamoto S., Leipzig J.N., Lieberman J.A., et al. Effects of ketamine, MK-801, and amphetamine on regional brain 2-deoxyglucose uptake in freely moving mice. Neuropsychopharmacology 22 (2000) 400-412
164. 11c]raclopride binding with no alterations in static dopamine concentrations in the striatal extracellular fluid in the monkey brain: multiparametric PET studies combined with microdialysis analysis. Synapse 37 (2000) 95-103
165. 11C]methamphetamine in monkeys in positron emission tomography (PET) study. Brain Res 911 (2001) 173-175
166. 11C]β-CIT-FE in the monkey brain. Synapse 42 (2001) 273-280
167. Elfving B., Bjørnholm B., and Knudsen G.M. Interference of anaesthetics with radioligand binding in neuroreceptor studies. Eur J Nucl Med Mol Imaging 30 (2003) 912-915
168. Votaw J.R., Byas-Smith M.G., Voll R., et al. Isoflurane alters the amount of dopamine transporter expressed on the plasma membrane in humans. Anesthesiology 101 (2004) 1128-1135
169. Hoffman B.J., Mezey E., and Brownstein M.J. Cloning of a serotonin transporter affected by antidepressants. Science 254 (1991) 579-580
170. Cortés R., Soriano E., Pazos A., et al. Autoradiography of antidepressant binding sites in the human brain: localization using [3h]imipramine and [3h]paroxetine. Neuroscience 27 (1988) 473-496
171. 3H]imipramine localization and relationship to serotonin transporter. J Pharmacol Exp Ther 252 (1990) 410-418
172. Fujita M., Shimada S., Maeno H., et al. Cellular localization of serotonin transporter mRNA in the rat brain. Neurosci Lett 162 (1993) 59-62
173. Austin M.C., Bradley C.C., Mann J.J., et al. Expression of serotonin transporter messenger RNA in the human brain. J Neurochem 62 (1994) 2362-2367
174. Blakely R.D., De Felice L.J., and Hartzell H.C. Molecular physiology of norepinephrine and serotonin transporters. J Exp Biol 196 (1994) 263-281
175. 3H]cyanoimipramine for quantitative measurement of serotonin transporter sites in human brain. Neuropsychopharmacology 14 (1996) 309-323
176. Stockmeier C.A., Shapiro L.A., Haycock J.W., et al. Quantitative subregional distribution of serotonin-1A receptors and serotonin
177. Kish S.J., Furukawa Y., Chang L.J., et al. Regional distribution of serotonin transporter protein in postmortem human brain. Is the cerebellum a SERT-free brain region?. Nucl Med Biol 32 (2005) 123-128
178. 3H]citalopram. Neuroscience 54 (1993) 691-699
179. 3H]imipramine binding sites in control and parkinsonian brains. Eur J Pharmacol 117 (1985) 71-80
180. Blier P., and de Montigny C. Serotonin and drug-induced therapeutic responses in major depression, obsessive-compulsive and panic disorders. Neuropsychopharmacology 21 (1999) 91S-98S
181. Chaouloff F., Berton O., and Mormede P. Serotonin and stress. Neuropsychopharmacology 21 (1999) 28S-32S
182. Lucki I. The spectrum of behaviors influenced by serotonin. Biol Psychiatry 44 (1998) 151-162
183. Mann J.J. Role of the serotonergic system in the pathogenesis of major depression and suicidal behavior. Neuropsychopharmacology 21 (1999) 99S-105S
184. Mann J.J., Brent D.A., and Arango V. The neurobiology and genetics of suicide and attempted suicide: a focus on the serotonergic system. Neuropsychopharmacology 24 (2001) 467-477
185. Owens M.J., and Nemeroff C.B. Role of serotonin in the pathophysiology of depression: focus on the serotonin transporter. Clin Chem 40 (1994) 288-295
186. Owens M.J., and Nemeroff C.B. The serotonin transporter and depression. Depress Anxiety 8 Suppl 1 (1998) 5-12
187. Purselle D.C., and Nemeroff C.B. Serotonin transporter: a potential substrate in the biology of suicide. Neuropsychopharmacology 28 (2003) 613-619
188. Benmansour S., Cecchi M., Morilak D.A., et al. Effects of chronic antidepressant treatments on serotonin transporter function, density, and mRNA level. J Neurosci 19 (1999) 10494-10501
189. Benmansour S., Owens W.A., Cecchi M., et al. Serotonin clearance in vivo is altered to a greater extent by antidepressant-induced downregulation of the serotonin transporter than by acute blockade of this transporter. J Neurosci 22 (2002) 6766-6772
190. Ramsey I.S., and De Felice L.J. Serotonin transporter function and pharmacology are sensitive to expression level. J Biol Chem 277 (2002) 14475-14482
191. Kugaya A., Sanacora G., Staley J.K., et al. Brain serotonin transporter availability predicts treatment response to selective serotonin reuptake inhibitors. Biol Psychiatry 56 (2004) 497-502
192. Mirza N.R., Nielsen E., and Troelsen K.B. Serotonin transporter density and anxiolytic-like effects of antidepressants in mice. Prog Neuropsychopharmacol Biol Psychiatry 31 (2007) 858-866
193. Stokes P.E. Ten years of fluoxetine. Depress Anxiety 8 Suppl 1 (1998) 1-4
194. 11C]fluoxetine in a monkey brain. Nucl Med Biol 22 (1995) 613-616
195. 18F-fluoxetine in the rodent brain: an in vitro and in vivo study. Nucl Med Biol 25 (1998) 605-610
196. Shank R.P., Vaught J.L., Pelley K.A., et al. McN-5652: a highly potent inhibitor of serotonin uptake. J Pharmacol Exp Ther 247 (1988) 1032-1038
197. Suehiro M., Scheffel U., Dannals R.F., et al. A PET radiotracer for studying serotonin uptake sites: carbon-11-McN-5652Z. J Nucl Med 34 (1993) 120-127
198. 11C](+)McN5652. Synapse 20 (1995) 37-43
199. 18F]fluoromethyl)-(+)-McN5652 as a potential PET radioligand for the serotonin transporter. Nucl Med Biol 28 (2001) 857-863
200. 18F]fluoromethyl-(+)-McN5652, a PET tracer for the serotonin transporter: evaluation in rats. Synapse 47 (2003) 45-53
201. Brust P., Hinz R., Kuwabara H., et al. In vivo measurement of the serotonin transporter with (S)-([18F]fluoromethyl)-(+)-McN5652. Neuropsychopharmacology 28 (2003) 2010-2019
202. 18F]fluoromethyl)-(+)-McN5652. Synapse 47 (2003) 143-151
203. 18F]fluoromethyl)-(+)-McN5652. Eur Neuropsychopharmacol 13 (2003) 387-397
204. 3H]6-nitroquipazine binding sites in rat brain. Eur J Pharmacol 180 (1990) 273-281
205. Karramkam M., Dollé F., Valette H., et al. Synthesis of a fluorine-18-labelled derivative of 6-nitroquipazine, as a radioligand for the in vivo serotonin transporter imaging with PET. Bioorg Med Chem 10 (2002) 2611-2623
206. 18F]fluoropropyl)-6-nitroquipazine. Bioorg Med Chem 11 (2003) 4949-4958
207. Mehta NB, Hollingsworth CEB, Brieaddy LE, et al. Halogen substituted diphenylsulfides. 1990: European Patent Application EP0 402 097 A1. Published December, 12, 1990.
208. Ferris R.M., Brieaddy L., Mehta N., et al. Pharmacological properties of 403U76, a new chemical class of 5-hydroxytryptamine and noradrenaline reuptake inhibitor. J Pharm Pharmacol 47 (1995) 775-781
209. Huang Y., Hwang D.R., Narendran R., et al. Comparative evaluation in nonhuman primates of five PET radiotracers for imaging the serotonin transporters: [11C]McN5652, [11C]ADAM, [11C]DASB, [11C]DAPA, and [11C]AFM. J Cereb Blood Flow Metab 22 (2002) 1377-1398
210. Jarkas N., Votaw J.R., Voll R.J., et al. Carbon-11 HOMADAM: a novel PET radiotracer for imaging serotonin transporters. Nucl Med Biol 32 (2005) 211-224
211. Jarkas N., McConathy J., Votaw J.R., et al. Synthesis and characterization of eadam: a selective radioligand for mapping the brain serotonin transporters by positron emission tomography. Nucl Med Biol 32 (2005) 75-86
212. 11C]AFA). Nucl Med Biol 31 (2004) 727-738
213. 18F-ADAM): an improved PET radioligand for serotonin transporters. J Nucl Med 44 (2003) 1890-1897
214. 11C]AFM). Nucl Med Biol 31 (2004) 543-556
215. 11C]AFE is a selective serotonin transporter ligand with fast brain uptake kinetics. Nucl Med Biol 31 (2004) 983-994
216. Huang Y., Bae S., Zhu Z., et al. Fluorinated diaryl sulfides as serotonin transporter ligands: synthesis, structure-activity relationship study, and in vivo evaluation of fluorine-18-labeled compounds as PET imaging agents. J Med Chem 48 (2005) 2559-2570
217. 18F(2-[2-Amino-5-fluorophenyl)thio]- N, N-dimethyl-benzenmethanamine as a PET imaging agent for serotonin transporters. J Labelled Comp Radiopharm 46 Suppl 1 (2003) S164
218. Oya S., Choi S.R., Coenen H., et al. New PET imaging agent for the serotonin transporter: [18F]ACF (2-[(2-amino-4-chloro-5-fluorophenyl)thio]- N, N-dimethyl-benzenmethanamine). J Med Chem 45 (2002) 4716-4723
219. Parhi A.K., Wang J.L., Oya S., et al. 2-(2'-((Dimethylamino)methyl)-4'-(fluoroalkoxy)-phenylthio)benzenamine derivatives as serotonin transporter imaging agents. J Med Chem 50 (2007) 6673-6684
220. Jarkas N., Voll R.J., Williams L., et al. Synthesis and in vivo evaluation of halogenated N, N-dimethyl-2-(2'-amino-4'-hydroxymethylphenylthio)benzylamine derivatives as PET serotonin transporter ligands. J Med Chem 51 (2008) 271-281
221. Oya S., Choi S.R., Hou C., et al. 2-((2-((Dimethylamino)-methyl)phenyl)thio)-5-iodophenylamine (ADAM): an improved serotonin transporter ligand. Nucl Med Biol 27 (2000) 249-254
222. Wilson A.A., Ginovart N., Schmidt M., et al. Novel radiotracers for imaging the serotonin transporter by positron emission tomography: synthesis, radiosynthesis, and in vitro and ex vivo evaluation of 11C-labeled 2-(phenylthio)araalkylamines. J Med Chem 43 (2000) 3103-3110
223. 11C]DASB. Eur J Nucl Med 27 (2000) 1719-1722
224. Ginovart N., Wilson A.A., Meyer J.H., et al. Positron emission tomography quantification of [11C]-DASB binding to the human serotonin transporter: modeling strategies. J Cereb Blood Flow Metab 21 (2001) 1342-1353
225. 11C-McN 5652 in healthy humans. J Nucl Med 45 (2004) 682-694
226. Frankle W.G., Narendran R., Huang Y., et al. Serotonin transporter availability in patients with schizophrenia: a positron emission tomography imaging study with [11C]DASB. Biol Psychiatry 57 (2005) 1510-1516
227. 11C-HOMADAM binding to the serotonin transporter in the healthy human brain. J Nucl Med 49 (2008) 2018-2025
228. Huang Y., Zhu Z., Bae S.A., et al. Comparison of three F-18 labeled PET ligands for the serotonin transporter: radiosynthesis and in vivo imaging studies in baboon. J Labelled Comp Radiopharm 46 Suppl 1 (2003) S57
229. 18F]-ADAM) as a serotonin transporter imaging agent. Appl Radiat Isot 61 (2004) 1247-1254
230. 18F]fluoropropoxy)-phenylthio)benzenamine for positron emission tomography imaging of serotonin transporters. Nucl Med Biol 35 (2008) 447-458
231. Owens M.J., Knight D.L., and Nemeroff C.B. Second-generation SSRIs: human monoamine transporter binding profile of escitalopram and R-fluoxetine. Biol Psychiatry 50 (2001) 345-350
232. Elfving B., and Wiborg O. Binding of S-citalopram and paroxetine discriminates between species. Synapse 55 (2005) 280-282
233. 3H]Nisoxetine: a radioligand for quantitation of norepinephrine uptake sites by autoradiography or by homogenate binding. J Pharmacol Exp Ther 260 (1992) 427-436
234. 3H]noradrenaline uptake and effects of DSP-4 lesioning and antidepressant treatments. Neuropharmacology 35 (1996) 63-70
235. Stehouwer J.S., Jarkas N., Zeng F., et al. Synthesis, radiosynthesis, and biological evaluation of carbon-11 labeled 2β-carbomethoxy-3β-(3′-((Z)-2-haloethenyl)phenyl)nortrop anes: candidate radioligands for in vivo imaging of the serotonin transporter with positron emission tomography. J Med Chem 49 (2006) 6760-6767
236. Wong E.H.F., Sonders M.S., Amara S.G., et al. Reboxetine: a pharmacologically potent, selective, and specific norepinephrine reuptake inhibitor. Biol Psychiatry 47 (2000) 818-829
237. Goodman M.M., Chen P., Plisson C., et al. Synthesis and characterization of iodine-123 labeled 2β-carbomethoxy-3β-(4'-((Z)-2-iodoethenyl)phenyl)nortropane: a ligand for in vivo imaging of serotonin transporters by single-photon-emission tomography. J Med Chem 46 (2003) 925-935
238. Plaznik A., Danysz W., Kostowski W., et al. Interaction between noradrenergic and serotonergic brain systems as evidenced by behavioral and biochemical effects of microinjections of adrenergic agonists and antagonists into the medial raphe nucleus. Pharmacol Biochem Behav 19 (1983) 27-32
239. Ordway G.A., Stockmeier C.A., Cason G.W., et al. Pharmacology and distribution of norepinephrine transporters in the human locus coeruleus and raphe nuclei. J Neurosci 17 (1997) 1710-1719
240. Ressler K.J., and Nemeroff C.B. Role of serotonergic and noradrenergic systems in the pathophysiology of depression and anxiety disorders. Depress Anxiety 12 Suppl 1 (2000) 2-19
241. Emond P., Vercouillie J., Innis R., et al. Substituted diphenyl sulfides as selective serotonin transporter ligands: synthesis and in vitro evaluation. J Med Chem 45 (2002) 1253-1258
242. 18F]fluorobenzyl)methylamino)methylphenylsulfanyl)benzonitri le, an F-18 fluorobenzyl analogue of DASB: synthesis, in vitro binding, and in vivo biodistribution studies. Bioconjug Chem 18 (2007) 1612-1618
243. Mavel S., Vercouillie J., Garreau L., et al. Docking study, synthesis, and in vitro evaluation of fluoro-MADAM derivatives as SERT ligands for PET imaging. Bioorg Med Chem 16 (2008) 9050-9055
244. Boja J., Kuhar M.J., Kopajtic T., et al. Secondary amine analogues of 3β-(4'-substituted phenyl)tropane-2β-carboxylic acid esters and N-norcocaine exhibit enhanced affinity for serotonin and norepinephrine transporters. J Med Chem 37 (1994) 1220-1223
245. Blough B.E., Abraham P., Lewin A.H., et al. Synthesis and transporter binding properties of 3β-(4'-alkyl-, 4'-alkenyl-, and 4'-alkynylphenyl)nortropane-2β-carboxylic acid methyl esters: serotonin transporter selective analogs. J Med Chem 39 (1996) 4027-4035
246. Blogh B.E., Abraham P., Mills A.C., et al. 3β-(4-Ethyl-3-iodophenyl)nortropane-2β-carboxylic acid methyl ester as a high-affinity selective ligand for the serotonin transporter. J Med Chem 40 (1997) 3861-3864
247. Tamagnan G., Baldwin R.M., Kula N.S., et al. Synthesis and monoamine transporter affinity of 2β-carbomethoxy-3β-(2'-, 3'- or 4'-substituted) biphenyltropanes. Bioorg Med Chem Lett 10 (2000) 1783-1785
248. Emond P., Helfenbein J., Chalon S., et al. Synthesis of tropane and nortropane analogues with phenyl substitutions as serotonin transporter ligands. Bioorg Med Chem 9 (2001) 1849-1855
249. Bois F., Baldwin R.M., Kula N.S., et al. Synthesis and monoamine transporter affinity of 3'-analogs of 2-β-carbomethoxy-3-β-(4'-iodophenyl)tropane (β-CIT). Bioorg Med Chem Lett 14 (2004) 2117-2120
250. Tamagnan G., Alagille D., Fu X., et al. Synthesis and monoamine transporter affinity of new 2β-carbomethoxy-3β-[4-(substituted thiophenyl)]phenyltropanes: discovery of a selective SERT antagonist with picomolar potency. Bioorg Med Chem Lett 15 (2005) 1131-1133
251. Tamagnan G., Alagille D., Fu X., et al. Synthesis and monoamine transporter affinity of new 2β-carbomethoxy-3β-[aryl or heteroaryl]phenyltropanes. Bioorg Med Chem Lett 16 (2006) 217-220
252. Bergström K.A., Halldin C., Hall H., et al. In vitro and in vivo characterisation of Nor-β-CIT: a potential radioligand for visualisation of the serotonin transporter in the brain. Eur J Nucl Med 24 (1997) 596-601
253. Helfenbein J., Sandell J., Halldin C., et al. PET examination of three potent cocaine derivatives as specific radioligands for the serotonin transporter. Nucl Med Biol 26 (1999) 491-499
254. Stehouwer J.S., Plisson C., Jarkas N., et al. Synthesis, radiosynthesis, and biological evaluation of carbon-11 and fluorine-18 (N-fluoroalkyl) labeled 2β-carbomethoxy-3β-(4'-(3-furyl)phenyl)-tropanes and -nortropanes: candidate radioligands for in vivo imaging of the serotonin transporter with positron emission tomography. J Med Chem 48 (2005) 7080-7083
255. Plisson C., Jarkas N., McConathy J., et al. Evaluation of carbon-11-labeled 2β-carbomethoxy-3β-[4'-((Z)-2-iodoethenyl)phenyl]nortropane as a potential radioligand for imaging the serotonin transporter by PET. J Med Chem 49 (2006) 942-946
256. Plisson C., Stehouwer J.S., Voll R.J., et al. Synthesis and in vivo evaluation of fluorine-18 and iodine-123 labeled 2β-carbo(2-fluoroethoxy)-3β-(4'-((Z)-2-iodoethenyl)phenyl)nort ropane as a candidate serotonin transporter imaging agent. J Med Chem 50 (2007) 4553-4560
257. Stehouwer J.S., Jarkas N., Zeng F., et al. Synthesis, radiosynthesis, and biological evaluation of fluorine-18-labeled 2β-carbo(fluoroalkoxy)-3β-(3'-((Z)-2-haloethenyl)phenyl)nortro panes: candidate radioligands for in vivo imaging of the serotonin transporter with positron emission tomography. J Med Chem 51 (2008) 7788-7799
258. Pacholczyk T., Blakely R.D., and Amara S.G. Expression cloning of a cocaine- and antidepressant-sensitive human noradrenaline transporter. Nature 350 (1991) 350-354
259. Schroeter S., Apparsundaram S., Wiley R.G., et al. Immunolocalization of the cocaine- and antidepressant-sensitive 1-norepinephrine transporter. J Comp Neurol 420 (2000) 211-232
260. Sara S.J. The locus coeruleus and noradrenergic modulation of cognition. Nat Rev Neurosci 10 (2009) 211-223
261. Rommelfanger K.S., and Weinshenker D. Norepinephrine: the redheaded stepchild of Parkinson's disease. Biochem Pharmacol 74 (2007) 177-190
262. Biederman J., and Spencer T. Attention-deficit/hyperactivity disorder (ADHD) as a noradrenergic disorder. Biol Psychiatry 46 (1999) 1234-1242
263. Bymaster F.P., Katner J.S., Nelson D.L., et al. Atomoxetine increases extracellular levels of norepinephrine and dopamine in prefrontal cortex of rat: a potential mechanism for efficacy in attention deficit/hyperactivity disorder. Neuropsychopharmacology 27 (2002) 699-711
264. Southwick S.M., Bremner D.J., Rasmusson A., et al. Role of norepinephrine in the pathophysiology and treatment of posttraumatic stress disorder. Biol Psychiatry 46 (1999) 1192-1204
265. Ressler K.J., and Nemeroff C.B. Role of norepinephrine in the pathophysiology and treatment of mood disorders. Biol Psychiatry 46 (1999) 1219-1233
266. Van Moffaert M., and Dierick M. Noradrenaline (norepinephrine) and depression: role in aetiology and therapeutic implications. CNS Drugs 12 (1999) 293-305
267. Zhu M.Y., Klimek V., Dilley G.E., et al. Elevated levels of tyrosine hydroxylase in the locus coeruleus in major depression. Biol Psychiatry 46 (1999) 1275-1286
268. Ahern T.H., Javors M.A., Eagles D.A., et al. The effects of chronic norepinephrine transporter inactivation on seizure susceptibility in mice. Neuropsychopharmacology 31 (2006) 730-738
269. Klimek V., Stockmeier C., Overholser J., et al. Reduced levels of norepinephrine transporters in the locus coeruleus in major depression. J Neurosci 17 (1997) 8451-8458
270. Logan J., Ding Y.S., Lin K.S., et al. Modeling and analysis of PET studies with norepinephrine transporter ligands: the search for a reference region. Nucl Med Biol 32 (2005) 531-542
271. Ding Y.S., Lin K.S., and Logan J. PET imaging of norepinephrine transporters. Curr Pharm Des 12 (2006) 3831-3845
272. Schou M., Pike V.W., and Halldin C. Development of radioligands for imaging of brain norepinephrine transporters in vivo with positron emission tomography. Curr Top Med Chem 7 (2007) 1806-1816
273. Patient selection and antidepressant therapy with reboxetine, a new selective norepinephrine reuptake inhibitor. J Clin Psychiatry 59 Suppl 14 (1998)
274. Brenner E., Baldwin R.M., and Tamagnan G. Asymmetric synthesis of (+)-(S, S)-reboxetine via a new (S)-2-(hydroxymethyl)morpholine preparation. Org Lett 7 (2005) 937-939
275. Ding Y.S., Lin K.S., Garza V., et al. Evaluation of a new norepinephrine transporter PET ligand in baboons, both in brain and peripheral organs. Synapse 50 (2003) 345-352
276. Wilson A.A., Johnson D.P., Mozley D., et al. Synthesis and in vivo evaluation of novel radiotracers for the in vivo imaging of the norepinephrine transporter. Nucl Med Biol 30 (2003) 85-92
277. Schou M., Halldin C., Sóvágó J., et al. Specific in vivo binding to the norepinephrine transporter demonstrated with the PET radioligand, (S, S)- [11C]MeNER. Nucl Med Biol 30 (2003) 707-714
278. Schou M., Halldin C., Sóvágó J., et al. PET evaluation of novel radiofluorinated reboxetine analogs as norepinephrine transporter probes in the monkey brain. Synapse 53 (2004) 57-67
279. 2. Eur Neuropsychopharmacol 15 (2005) 517-520
280. 2 in non-human primates. Nucl Med Commun 26 (2005) 695-700
281. 2: a human whole-body PET study. Eur J Nucl Med Mol Imaging 35 (2008) 630-636
282. Seneca N., Gulyás B., Varrone A., et al. Atomoxetine occupies the norepinephrine transporter in a dose-dependent fashion: a PET study in nonhuman primate brain using (S, S)- [18F]FMeNER-D2. Psychopharmacology 188 (2006) 119-127
283. 2. Eur J Nucl Med Mol Imaging 35 (2008) 153-157
284. Lin K.S., Ding Y.S., Kim S.W., et al. Synthesis, enantiomeric resolution, F-18 labeling and biodistribution of reboxetine analogs: promising radioligands for imaging the norepinephrine transporter with positron emission tomography. Nucl Med Biol 32 (2005) 415-422
285. Ding Y.S., Lin K.S., Logan J., et al. Comparative evaluation of positron emission tomography radiotracers for imaging the norepinephrine transporter: (S, S) and (R, R) enantiomers of reboxetine analogs ([11C]methylreboxetine, 3-Cl- [11C]methylreboxetine and [18F]fluororeboxetine), (R)- [11C]nisoxetine, [11C]oxaprotiline and [11C]lortalamine. J Neurochem 94 (2005) 337-351
286. Zeng F., Jarkas N., Stehouwer J.S., et al. Synthesis, in vitro characterization, and radiolabeling of reboxetine analogs as potential PET radioligands for imaging the norepinephrine transporter. Bioorg Med Chem 16 (2008) 783-793
287. Zeng F., Mun J., Jarkas N., et al. Synthesis, radiosynthesis, and biological evaluation of carbon-11 and fluorine-18 labeled reboxetine analogues: potential positron emission tomography radioligands for in vivo imaging of the norepinephrine transporter. J Med Chem 52 (2009) 62-73
288. Hara K., Yanagihara N., Minami K., et al. Ketamine interacts with the noradrenaline transporter at a site partly overlapping the desipramine binding site. Naunyn Schmiedebergs Arch Pharmacol 358 (1998) 328-333
289. Blough B.E., Holmquist C.R., Abraham P., et al. 3α-(4-Substituted phenyl)nortropane-2β-carboxylic acid methyl esters show selective binding at the norepinephrine transporter. Bioorg Med Chem Lett 10 (2000) 2445-2447
290. Hoepping A., Johnson K.M., George C., et al. Novel conformationally constrained tropane analogues by 6- endo-trig radical cyclization and stille coupling: switch of activity toward the serotonin and/or norepinephrine transporter. J Med Chem 43 (2000) 2064-2071
291. Tamiz A.P., Smith M.P., and Kozikowski A.P. Design, synthesis and biological evaluation of 7-azatricyclodecanes: analogues of cocaine. Bioorg Med Chem Lett 10 (2000) 297-300
292. Zhou J., Zhang A., Kläss T., et al. Biaryl analogues of conformationally constrained tricyclic tropanes as potent and selective norepinephrine reuptake inhibitors: synthesis and evaluation of their uptake inhibition at monoamine transporter sites. J Med Chem 46 (2003) 1997-2007
293. Carroll F.I., Tyagi S., Blough B.E., et al. Synthesis and monoamine transporter binding properties of 3α-(substituted phenyl)nortropane-2β-carboxylic acid methyl esters: norepinephrine transporter selective compounds. J Med Chem 48 (2005) 3852-3857
294. Zhou J., Kläß T., Johnson K.M., et al. Discovery of novel conformationally constrained tropane-based biaryl and arylacetylene ligands as potent and selective norepinephrine transporter inhibitors and potential antidepressants. Bioorg Med Chem Lett 15 (2005) 2461-2465
295. Zeng F., Jarkas N., Owens M.J., et al. Synthesis and monoamine transporter affinity of front bridged tricyclic 3β-(4'-halo or 4'-methyl)phenyltropanes bearing methylene or carbomethoxymethylene on the bridge to the 2β-position. Bioorg Med Chem Lett 16 (2006) 4661-4663
296. Eildal J.N.N., Andersen J., Kristensen A.S., et al. From the selective serotonin transporter inhibitor citalopram to the selective norepinephrine transporter inhibitor talopram: synthesis and structure-activity relationship studies. J Med Chem 51 (2008) 3045-3048
297. 11C]talsupram: candidate PET ligands for the norepinephrine transporter. Nucl Med Biol 31 (2004) 705-718